Digital Repository

Metformin: use as a pharmacological agent in management of childhood obesity

Show simple item record

dc.contributor.author Warnakulasuriya, L.S.
dc.contributor.author Fernando, M.A.M.
dc.contributor.author Adikaram, A.V.N.
dc.contributor.author Thawfeek, A.R.M.
dc.contributor.author Anurasiri, W.M.L.
dc.contributor.author Silva, K.D.R.R.
dc.contributor.author Sirasa, M.S.F.
dc.contributor.author Samaranayake, D.
dc.contributor.author Wickramasinghe, V.P.
dc.date.accessioned 2017-09-12T09:37:04Z
dc.date.available 2017-09-12T09:37:04Z
dc.date.issued 2016
dc.identifier.citation Sri Lanka Medical Association, 129th Anniversary International Medical Congress. 2016: 136 en_US
dc.identifier.issn 0009-0895
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/17417
dc.description Oral Presentation Abstract (OP 56), 129th Anniversary International Medical Congress, Sri Lanka Medical Association, 25-27 July 2016 Colombo, Sri Lanka en_US
dc.description.abstract INTRODUCTION: Childhood obesity-related metabolic derangements are increasing among South Asian populations. Dietary and physical activity plans have limited effect. OBJECTIVES: This study aims to assess effectiveness of metformin against placebo in management of childhood obesity among 8-16 year-old children in Gampaha District. METHOD: A triple-blinded control trial was conducted in a sample of 150 obese school children. After 12-hour overnight fast, blood was drawn for fasting blood glucose (FBS) and lipid profile. 2-hour OGTT was done. Anthropometry, fat mass (FM) and blood pressure were measured. Children randomly received either age-adjusted dose of metformin or placebo, with advice on diet and physical activity. Anthropometry and blood investigations were repeated at 6 and 12 months. Mean difference in outcome measures, adjusted for baseline values were compared between the two groups using ANOVA. RESULTS: There were 84/150 boys and 25 (16.7%) had metabolic syndrome. A statistically significant adjusted mean reduction was observed in metformin group compared to placebo, in weight (-0.991 vs 1.394, p=0.000), BMI-SDS (-0.287 vs -0.116, p=0.000), percentage FM-SDS (-0.092 vs 0.016, p=0.04), systolic BP (-0.415 vs 0.015, p=0.015), total cholesterol (-36.48 vs -27.32, p=0.001), LDL (-26.06 vs -17.22, p=0.001) and hsCRP(-0.143 vs 0.008, p=0.013) at six months, and in BMI-SDS (-370 vs -0.222, p=0.001), WC-SDS (-0.473 vs -0.337, p=0.018), systolic BP (-0.834 vs -0.477, p=0.023) and triglycerides (-29.30 vs-12,72, p=0.019) at 12 months. CONCLUSIONS: Metformin compared to placebo has beneficial effects on anthropometric and metabolic indicators in the management of childhood obesity. en_US
dc.language.iso en_US en_US
dc.publisher Sri Lanka Medical Association en_US
dc.subject Metformin en_US
dc.title Metformin: use as a pharmacological agent in management of childhood obesity en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference Papers
    Papers presented at local and international conferences by the Staff of the Faculty of Medicine

Show simple item record

Search Digital Repository


Browse

My Account